Danny Ko

Danny Ko is a Senior Scientist at Epic Bio, where they focus on establishing efficient combinatorial screens to identify optimal modulators and sgRNAs for CART therapy. Previously, they held roles as Scientist I and II at Epic Bio, contributing to high throughput screening methodologies and developing targeted single-cell RNAseq approaches for various projects. Danny earned a PhD in Biological and Biomedical Sciences from Louisiana State University after identifying novel genes associated with cisplatin resistance in human melanoma. They began their scientific career as a Research Associate at Anacor Pharmaceuticals and later worked as a Senior Associate Scientist at Amgen, focusing on cell line development. Danny holds a Bachelor of Science in Biochemistry from the University of California, Santa Barbara.